CRP and rheumatoid arthritis: Moreover, these data suggest that rather than having a direct effect on bone, the contribution of FOXO3 to outcome in RA is likely to be by modulating inflammation (e.g., the CRP level) and disease activity (e.g., swollen joint count, DAS28), which would then lead to differences in radiographic outcome (e.g., Larsen score, erosions).